| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803097301016 | 309730101 | ODYRAL EY.DRO.SOL 20MG/ML 1 VIAL (LDPE) x 5,0ML | 2.23 | 2.34 | 3.22 |
| 05/2018 | 2803097301023 | 309730102 | ODYRAL EY.DRO.SOL 20MG/ML 3 VIALS (LDPE) x 5,0ML | 06.02 | 6.31 | 8.69 |
| 05/2018 | 2803097301030 | 309730103 | ODYRAL EY.DRO.SOL 20MG/ML 6 VIALS (LDPE) x 5,0ML | 12.04 | 12.63 | 17.41 |
For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
Dorzolamide is a sulfonamide and a highly specific carbonic anhydrase II (CA-II) inhibitor, which is the main CA isoenzyme involved in aqueous humor secretion. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Dorzolamide also accumulates in red blood cells as a result of CA-II binding, as CA-II is found predominantly in erythrocytes. However, sufficient CA-II activity remains so that adverse effects due to systemic CA inhibition are not observed.
Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest
4 months
Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine.